Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer

• Main Authors: Dent, R.A, Lindeman, G.J, Clemons, M, Wildiers, H, Chan, A, McCarthy, N.J, Singer, C.F, Lowe, E.S, Watkins, C.L, Carmichael, J
• Other Authors: DUKE-NUS MEDICAL SCHOOL
• Format: Article
• Published: 2020
• Subjects: granulocyte colony stimulating factor; olaparib; paclitaxel; taxane derivative; antineoplastic agent; nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase; phthalazine derivative; piperazine derivative; adult; alopecia; anemia; aphasia; article; bilirubin blood level; breast metastasis; cancer combination chemotherapy; cancer growth; cancer mortality; cause of death; clinical article; constipation; continuous infusion; diarrhea; drug dose reduction; drug efficacy; drug safety; drug tolerability; drug withdrawal; fatigue; female; fever; gamma glutamyl transferase blood level; herpes zoster; human; lactate dehydrogenase blood level; mastitis; monotherapy; multicenter study; multiple cycle treatment; multiple organ failure; nausea; neutropenia; neutrophil count; optimal drug dose; peripheral neuropathy; phase 1 clinical trial; progression free survival; rash; side effect; skin disease; skin infection; treatment duration; treatment response; triple negative breast cancer; vomiting; aged; cohort analysis; drug antagonism; metastasis; middle aged; mortality; pathology; treatment outcome; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerases; Treatment Outcome; Triple Negative Breast Neoplasms
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/183198
• Institution: National University of Singapore

10.1186/bcr3484